Hyperlipidemia and cardiovascular disease

Current Opinion in Lipidology

Volumn 23, Issue 6, 2012, Pages 591-592

  Malloy, Mary J ^a   Kane, John P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHYLOMICRON; CHYLOMICRON REMNANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; PLASMINOGEN; VERY LOW DENSITY LIPOPROTEIN;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DISEASE SEVERITY; FIBRINOLYSIS; HEART CATHETERIZATION; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; NOTE; PRIORITY JOURNAL;

ANIMALS; ATHEROSCLEROSIS; CHYLOMICRONS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEIN(A); RISK FACTORS;

EID: 84870001942     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328359f162     Document Type: Note

References (13)

1. Nakajima K, Nakano T, Tokita Y, et al. Postprandial lipoprotein metabolism: VLDL vs. chylomicrons. Clin Chim Acta 2011; 412:1306-1318. During the absorption of ingested triglycerides, the level of chylomicrons in blood increases, but the delivery of triglycerides to liver in chylomicron remnants stimulates the secretion of very-low-density lipoproteins. Thus the increase in circulating triglycerides is not solely due to chylomicronemia.
2. Masuda D, Sugimoto T, Tsujii KI, et al. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest 2012; 42:992-999. This documents a significant relationship between circulating levels of particles of chylomicron origin and the extent of angiographically assessed coronary atherosclerosis.
3. Kim JY, Park JH, Jeong SW, et al. High levels of remnant lipoprotein cholesterol is a risk factor for large artery atherosclerotic stroke. J Clin Neurol 2011; 4:203-209. This study supports a strong relationship of chylomicron-derived lipoprotein particles with atherothrombotic stroke.
4. Nakatani K, Sugimoto T, Masuda D, et al. Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels. Atherosclerosis 2011; 218:226-232.
5. Fraser R, Cogger VC, Dobbs B, et al. The liver sieve and atherosclerosis. Pathology 2012; 44:181-186. The authors develop the role of the sinusoidal cells in liver in creating a semipermeable barrier that delays the uptake of triglyceride-rich chylomicrons and presumably large VLDL, and permits the selective uptake of their remnant particles. Factors affecting this function, either genetic or acquired, could result in increased levels of circulating atherogenic remnant lipoprotein particles.
6. Kwon SW, Lee BK, Hong BK, et al. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients. Int J Cardiol 2012 [Epub ahead of print].
7. Ban os-Gonzá lez MA, Anglés-Cano E, Cardoso-Saldana G, et al. Lipoprotein (a) and homocysteine potentiate the risk of coronary artery disease in male subjects. Circ J 2012; 76:1953-1957. The interaction of homocysteine, an established risk factor for atherosclerosis, with Lp(a), which may adversely affect fibrinolysis, is introduced.
8. Zhang C, Luo Y, Huang Z. Elevated serum b(2)-GPI-Lp(a) complexes levels in children with nephrotic syndrome. Clin Chim Acta 2012; 413:1657-1660. The revelation of the formation of a stable complex between Lp(a) and the b(2)-glycoprotein I protein will help to explain the role of Lp(a) in the pathophysiology of nephrosis.
9. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012; 60:716-721. This is an excellent review of the many faces of Lp(a) in human biology and disease.
10. Konerman M, Kulkarni K, Toth PP, Jones SR. Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups. J Clin Lipidol 2012; 6:368-373.
11. Murase T, Arimoto S, Okubo M, Morinaga S. Significant reduction of elevated serum lipoprotein(a) concentrations during levo-thyroxine replacement therapy in a hypothyroid patient. J Clin Lipidol 2012; 6:388-391. Individuals with high levels of Lp(a) should be screened for subclinical hypothyroidism.
12. Arai K, Orsoni A, Mallat Z, et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res 2012; 53:1670-1678. This study not only demonstrates the value of LDL apheresis with respect to Lp(a) levels, but relates Lp(a) to the level of oxidized lipids in blood, a probable factor in atherogenesis.
13. Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Am Coll Cardiol 2012; 60:716-721.